"Fibrinolysin" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A product of the lysis of plasminogen (profibrinolysin) by PLASMINOGEN activators. It is composed of two polypeptide chains, light (B) and heavy (A), with a molecular weight of 75,000. It is the major proteolytic enzyme involved in blood clot retraction or the lysis of fibrin and quickly inactivated by antiplasmins.
| Descriptor ID |
D005341
|
| MeSH Number(s) |
D08.811.277.656.300.760.330 D08.811.277.656.959.350.330
|
| Concept/Terms |
Fibrinolysin- Fibrinolysin
- Plasmin
- Protease F
- Glu-Plasmin
- Glu Plasmin
|
Below are MeSH descriptors whose meaning is more general than "Fibrinolysin".
Below are MeSH descriptors whose meaning is more specific than "Fibrinolysin".
This graph shows the total number of publications written about "Fibrinolysin" by people in this website by year, and whether "Fibrinolysin" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2010 | 1 | 0 | 1 |
| 2015 | 1 | 0 | 1 |
| 2017 | 1 | 1 | 2 |
| 2018 | 1 | 2 | 3 |
| 2019 | 1 | 1 | 2 |
| 2020 | 2 | 1 | 3 |
To return to the timeline, click here.
Below are the most recent publications written about "Fibrinolysin" by people in Profiles.
-
Fibrinolytic or anti-plasmin (nafamostat) therapy for COVID-19: A timing challenge for clinicians. Pulm Pharmacol Ther. 2021 10; 70:102055.
-
Vascular activation is a strong predictor of mortality in coronavirus disease 2019 patients on the ICU. Blood Coagul Fibrinolysis. 2021 Jun 01; 32(4):290-293.
-
Assessing Plasmin Generation in Health and Disease. Int J Mol Sci. 2021 Mar 09; 22(5).
-
Characterization of fibrin/fibrinogen degradation products reagents and their utility in critical care patients with enhanced fibrinolysis. Int J Lab Hematol. 2021 Aug; 43(4):813-820.
-
COVID-19 and Sepsis Are Associated With Different Abnormalities in Plasma Procoagulant and Fibrinolytic Activity. Arterioscler Thromb Vasc Biol. 2021 01; 41(1):401-414.
-
Consideration of Tranexamic Acid Administration to COVID-19 Patients. Physiol Rev. 2020 10 01; 100(4):1595-1596.
-
Anti-protease Treatments Targeting Plasmin(ogen) and Neutrophil Elastase May Be Beneficial in Fighting COVID-19. Physiol Rev. 2020 10 01; 100(4):1597-1598.
-
Circulating Plasminogen Concentration at Admission in Patients with Coronavirus Disease 2019 (COVID-19). Semin Thromb Hemost. 2020 10; 46(7):859-862.
-
Fibrinolysis and COVID-19: A tale of two sites? J Thromb Haemost. 2020 09; 18(9):2430-2432.
-
Specific coagulation markers may provide more therapeutic targets in COVID-19 patients receiving prophylactic anticoagulant. J Thromb Haemost. 2020 09; 18(9):2428-2430.